Fractyl Health, Inc. Common Stock (GUTS) is a publicly traded Healthcare sector company. As of May 21, 2026, GUTS trades at $0.91 with a market cap of $127.93M and a P/E ratio of -0.47. GUTS moved +12.56% today. Year to date, GUTS is -55.28%; over the trailing twelve months it is -56.13%. Its 52-week range spans $0.38 to $3.48. Analyst consensus is strong buy with an average price target of $5.00. Rallies surfaces GUTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Fractyl Health Secures Runway into Early 2027, Anticipates Q4 Pivotal Readout: Fractyl Health reiterated cash runway into early 2027 and affirmed key Revita® trial milestones, including REVEAL-1 1-year data in Q2 and REMAIN-1 pivotal topline results in early Q4 2026. The company also gained CTA approval for its RJVA-001 first-in-human T2D study, with dosing planned in H2 2026.
| Metric | Value |
|---|---|
| Price | $0.91 |
| Market Cap | $127.93M |
| P/E Ratio | -0.47 |
| EPS | $-1.86 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.48 |
| 52-Week Low | $0.38 |
| Volume | 4.75K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-140.95M |
| Gross Margin | 0.00% |
4 analysts cover GUTS: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.00.